Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Gainesville, Florida


To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.


Inclusion Criteria: - Men age 18-55 - Negative drug screen - Normal EKG, clinical chemistries, CBC, urinalysis, and - Give written informed consent Exclusion Criteria: - Active concomitant serious medical or surgical disease, - Hepatic or renal laboratory values above reference range, ise of other experimental drug within previous 30 days

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects

Official Title:

Phase 1 Study of Anti-glycation Agent GLY-230

Overall Status:


Study Phase:

Phase 1



Minimum Age:

18 Years

Maximum Age:

55 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:


Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification: P

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Laurence Kennedy
Principal Investigator
Univ. FLA Gainesville

Study Dates

Start Date:October 2005
Completion Date:October 2006
Completion Type:Actual
Primary Completion Date:October 2006
Primary Completion Type:Actual
Verification Date:February 2016
Last Changed Date:February 9, 2016
First Received Date:October 15, 2007

Study Outcomes

Outcome Type:Primary Outcome
Measure:A Dose-Ranging Study to Evaluate the Phamacokinetics and Safety of Six Single-Dose Levels of GLY-230 in Healthy Subjects
Time Frame:October, 2005 to October, 2006
Safety Issues:False

Study Interventions

Intervention Type:Drug
Arm Name:50 mg
Intervention Type:Other
Description:No drug administered
Arm Name:Placebo

Study Arms

Study Arm Type:Experimental
Arm Name:50 mg
Study Arm Type:Experimental
Arm Name:100 mg
Study Arm Type:Experimental
Arm Name:250 mg
Study Arm Type:Experimental
Arm Name:500 mg
Study Arm Type:Experimental
Arm Name:750 mg
Study Arm Type:Experimental
Arm Name:1000 mg
Study Arm Type:Placebo Comparator
Arm Name:Placebo

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Glycadia
Agency Class:Other
Agency Type:Collaborator
Agency Name:University of Florida

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.